Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.

ABSTRACT:

Background

Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease.

Methods

This study was an open-label crossover study. We enrolled Parkinson's disease patients on dopamine agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems. Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8 weeks respectively in a crossover manner without a washou

SUBMITTER: Yun JY 

PROVIDER: S-EPMC3766261 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature